




Rethinking neoadjuvant chemotherapy for breast
cancer
As evidence questioning the rationale behind neoadjuvant chemotherapy in breast cancer grows,
Jayant Vaidya and colleagues say we must reconsider the current treatment options
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Key messages
Neoadjuvant chemotherapy is being increasingly
used for breast cancer despite higher rates of
local recurrence and no evidence of survival
benefit, mainly because of the immediate and
dramatic pathological responses seen with
newer drugs
The increased pathological response of the
primary tumour does not translate into a survival
benefit even when given in the adjuvant setting,
challenging the paradigm of “window of
opportunity” studies
We must acknowledge that neoadjuvant
chemotherapy may not be beneficial to patients
We should consider reducing the widespread
use of neoadjuvant chemotherapy
Breast cancer is the most common cancer in women worldwide.
In 2014, 55 000 women in the UK were given the diagnosis of
breast cancer, and 11 000 died.1 Early breast cancer is
traditionally treated with surgery, plus radiotherapy and adjuvant
systemic therapy as required.
Neoadjuvant chemotherapy for breast cancer is a new strategy
that was introduced towards the end of the 20th century with
the aim of reducing tumour size. It has four main rationales.
Firstly, it should render an otherwise inoperable tumour operable
or, secondly, allow more conservative surgery. Thirdly, starting
systemic treatment preoperatively was hoped to lead to improved
overall survival in patients with locally advanced cancers, who
are at high risk of having distant disease. Finally, unlike adjuvant
chemotherapy given in the absence of any measurable disease,
neoadjuvant chemotherapy gives us the opportunity to observe
the tumour shrink both palpably and on imaging, enabling a
rapid assessment of clinical response. This could help test
responses in vivo to new drug regimens, which could then be
used as adjuvant therapies, in so called window of opportunity
studies.
A survey of multidisciplinary teams in Australia, Germany,
Italy, the UK, and the US found that 7-27% of new breast
cancers are treated with neoadjuvant chemotherapy (Saunders
C, Cody H, Kolberg HC, et al, personal communication, 2017).
With 1.7 million women receiving diagnoses annually, this
translates into 120 000-460 000 women receiving neoadjuvant
chemotherapy worldwide.1
Although data indicate that the first rationale remains valid, the
others have not led to the desired outcomes. More conservative
surgery after neoadjuvant chemotherapy can result in a higher
rate of local recurrence, and, despite the earlier initiation of
systemic treatment, no improvement in survival has been seen.2-4
Furthermore, neoadjuvant chemotherapy may not help test novel
chemotherapies—although primary tumour response is a good
indicator of prognosis for a particular treatment, it is
counterintuitively a poor surrogate marker for the overall
survival benefit when evaluating novel chemotherapy regimens.
Finally, for 40-80% of patients, even the best neoadjuvant
chemotherapy regimens extend the period the cancer remains
in the breast and can make surgery more difficult, as the tumour
is less easily palpable and the axillary lymph nodes are less
distinct. We question the wisdom of the current widespread use
of neoadjuvant chemotherapy.
Shrinking tumours to enable surgery
When a patient presents with a breast cancer so large that
mastectomy is technically not possible, neoadjuvant
chemotherapy may reduce its size, making it possible to do a
mastectomy with curative intent. But many such patients also
have distant metastases, so surgery is only performed for
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symptom control as it can worsen distant disease-free survival5;
this is a rare indication for neoadjuvant chemotherapy.
Breast conservation, local recurrence,
and survival
Data from several randomised clinical trials comparing
neoadjuvant with adjuvant chemotherapy have been analysed
in three well conducted meta-analyses, comprising about 4500
patients.2-4 Neoadjuvant chemotherapy did not confer any
survival benefit compared with adjuvant chemotherapy, with a
summary risk ratio of 1.00 (95% confidence interval 0.90 to
1.12) in Mauri et al2 and a hazard ratio of 0.98 (0.87 to 1.09) in
Mieog et al.3 After neoadjuvant chemotherapy, only 16.6%
patients overall eventually convert from mastectomy to breast
conservation, but they carry a statistically significantly higher
risk of locoregional recurrence (6% increase in absolute terms).2-4
If the surgery was less extensive than deemed necessary before
neoadjuvant chemotherapy, the rise in risk of local recurrence
was much larger. Even with intensive chemotherapy (using
paclitaxel and anthracycline), as in one trial included in the
meta-analysis, there was only a 29% improvement in breast
conservation rate.6 The Early Breast Cancer Trialists’
Collaborative Group’s meta-analysis, with individual patient
data from >4500 patients, had similar results: a higher local
recurrence with neoadjuvant chemotherapy.4 Doctors must
discuss with patients the benefits of breast preservation balanced




Neoadjuvant chemotherapy can enable in vivo assessment of
tumour response. The fundamental assumptions here are that
the characteristics and behaviour of the primary tumour are
representative of metastatic deposits and that response to
neoadjuvant chemotherapy will predict response to postoperative
adjuvant chemotherapy. Data from recent randomised trials
challenge these assumptions.
Firstly, a pathological complete response should mean that there
are truly no viable residual tumour cells. Traditional histology,
however, does not seem to detect all viable cells: randomised
trial data show that avoiding surgical excision of the original
tumour bed, even with an apparent pathological complete
response, leads to higher rates of local recurrence.2-4
Secondly, although pathological complete response of the
primary tumour has prognostic value in a particular study, it is
an unreliable surrogate marker for comparing breast cancer
outcomes across treatment regimens. An analysis across trials
by Cortazar et al found that increases in pathological complete
response did not correlate with improvements in overall survival
(R2=0.24) (⇓).17
Historically, some drugs that improve overall survival have also
had higher rates of pathological complete response in the
neoadjuvant setting (for example, aromatase inhibitors compared
with tamoxifen18 19 and trastuzumab compared with no
trastuzumab.20 21) But this finding is not consistent, and the
difference in overall survival is far smaller than the difference
in pathological response rates. Randomised trial data for three
new targeted therapies, which had dramatically higher
pathological complete response rates in the neoadjuvant
setting,22-24 found no survival benefit in the adjuvant setting for
lapatinib (ALTTO trial), bevacizumab (BEATRICE), or
pertuzumab (APHINITY).25-28 Neoadjuvant pertuzumab, for
example, had previously shown a near doubling of rates of
pathological complete response (22% v 39%)24 but found no
difference in overall survival in the adjuvant setting (⇓).28
These robust and consistent results should be enough to convince
regulators, such as the US Food and Drug Administration, that
they should not provide accelerated approval for drugs based
only on achieving a higher rate of pathological complete
response, which has the same pitfalls as other surrogate
endpoints.29
The finding that a positive correlation between pathological
complete response and overall survival for a new drug does not
always translate into a survival benefit is a major setback for
the window of opportunity paradigm of using neoadjuvant
chemotherapy for drug discovery.
Thirdly, if the primary tumour mimics the biology of metastatic
deposits, then patients with pathological complete response with
neoadjuvant chemotherapy might have had a similar response
in the adjuvant setting. If so, they may have fared even better,
as the disease burden is much lower in the adjuvant setting, and
there is no need to worry about the possibility of resistant clones
arising in the several months of neoadjuvant chemotherapy.
New targeted therapies increasingly have their first trials in
humans in the neoadjuvant setting. If they do not improve
pathological complete response, they may be discarded. But
this could be a mistake, as these drugs might improve survival
only in the adjuvant setting, when the tumour burden is very
low. For example, although in the neoadjuvant setting
trastuzumab seems to have much less benefit in oestrogen
receptor positive than negative tumours,22 its benefit in the
adjuvant setting does not seem different between oestrogen
receptor positive and negative tumours.30 31 If adjuvant trials had
not been published first, we may have excluded oestrogen
receptor positive cases in the adjuvant setting, and these patients
may have missed the benefits of trastuzumab.
Crucially, the definition of pathological complete response may
be wrong. Clearly, the current histopathological assessment
after neoadjuvant chemotherapy does not always correlate with
the clinical outcomes or biological behaviour of the tissue.
Improvements in imaging and pathological technology might
help identify occult malignant cells in cases that are currently
classified as having a complete pathological response.
Length of time that patients harbour a
large volume of tumour
Even with the best neoadjuvant chemotherapy regimen the
complete pathological response rate (breast plus axilla), is only
39%; 12% of patients have no response and 48% have partial
response or stable disease.24 32 The definition of stable disease
according to RECIST (response evaluation criteria in solid
tumours)33 allows growth up to 20% in the longest diameter,
which can represent a 73% increase in volume. Thus, despite
the best targeted treatment given to the appropriate population
(dual HER2 blockade with trastuzumab and pertuzumab in
HER2 positive cases), 60% of patients overall continue to live
with the disease containing aggressive chemoresistant cells,
throughout the 5-6 months of neoadjuvant chemotherapy. Even
those who ultimately have a pathological complete response
arguably continue to harbour a large volume of tumour for
several months before it fully responds. The additional detriment
of this delay in surgical excision might not be discernible in
older clinical trials, which mainly included patients with high
risk disease, but for the smaller and better prognosis tumours
that neoadjuvant chemotherapy is now being increasingly used
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for, it might be much more important to avoid this potentially
detrimental effect by performing earlier surgery. Importantly,
some patients find it psychologically difficult to live with the
cancer in their breasts for the duration of neoadjuvant
chemotherapy, particularly when it does not respond well, an
aspect that has not been considered in any randomised trial.
Neoadjuvant chemotherapy makes
surgical removal less precise
The lack of clearly palpable margins of the softer and diffuse
remnant tumour after neoadjuvant chemotherapy can reduce
the surgical precision of the wide local excision. This rarely
expressed difficulty might contribute to higher local recurrence
rates. Furthermore, a negative margin after a wide local excision
might not mean much, as the tumour is no longer a contiguous
structure but instead consists of multiple viable tumour islands
scattered throughout the original volume of tumour tissue. The
edges—and therefore margins—of this volume of tissue are
very difficult to define, whether by palpation, ultrasonography,
mammography, MRI, or even histopathology.
On the other hand, if patients underwent surgery first they would
immediately (or after a second surgery if the first left positive
margins) be rid of most of the disease, achieving a 100%
response rate at the primary site. Operating on a primary tumour
that is clearly palpable is technically much easier simply because
the surgeon’s fingers can define the edges. This is also true for
surgical treatment of untreated axilla as lymph nodes are rarely
fixed to surrounding structures, and an axillary clearance is
much easier when they are distinctly palpable, rather than the
fibrous tissue of uncertain significance that is encountered after
neoadjuvant chemotherapy.
Challenging the paradigm
Neoadjuvant chemotherapy has gained popularity in recent years
and is now being offered to patients with smaller tumours even
when upfront breast conservation is possible and to those with
larger tumours who will still require a mastectomy afterwards.
This is mainly because their cancers have certain biological
phenotypes that dramatically respond to neoadjuvant
chemotherapy; for example, HER2 positive cancers. That such
a response will be replicated in the metastatic sites of the tumour
has been disproven by randomised trial data.17 24 These data
should change the conceptual framework about cancer treatment.
We should go back to the drawing board and investigate
alternative approaches to window of opportunity studies.
The time may have come for a “medical reversal,”34 as new trial
data contradict current clinical practice of the widespread use
of neoadjuvant chemotherapy even for patients with HER2
positive or triple negative disease. Neoadjuvant chemotherapy
should be considered only in patients who are on the borderline
of being suitable for breast conservation, in whom a smaller
resection might be feasible if there is a response, and if the
tumour type is likely to respond. Even in such cases, a shared
decision should be taken in which all the advantages,
disadvantages, uncertainties, and, importantly, lack of survival
benefit, and higher risk of local recurrence are explained to the
patient.
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Figures
Correlation between treatment effect on pathological complete response and overall survival. Each circle corresponds to
one randomised comparison and the size of the circle represents the sample size. A=GeparQuattro (epirubicin plus
cyclophosphamide followed by docetaxel then capecitabine versus epirubicin plus cyclophosphamide followed by docetaxel)7;
B=GeparDuo8; C=GeparQuattro (epirubicin plus cyclophosphamide followed by docetaxel and capecitabine versus epirubicin
plus cyclophosphamide followed by docetaxel)7; D=EORTC 10994/BIG 1-009; E=PREPARE10 11; F=NSABP B-2712;
G=responders in GeparTrio13; H=non-responders in GeparTrio14; I=AGO 115; J=NOAH.16
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Sharp contrast between the large improvement in complete pathological response rates in the neoadjuvant setting and the
absence of survival benefit in the adjuvant setting.28
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